C3i Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • C3i's estimated annual revenue is currently $18.3M per year.(i)
  • C3i's estimated revenue per employee is $155,000

Employee Data

  • C3i has 118 Employees.(i)
  • C3i grew their employee count by 17% last year.

C3i's People

NameTitleEmail/Phone
1
VP OperationsReveal Email/Phone
2
Associate Director, ProgrammesReveal Email/Phone
3
Associate DirectorReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Directrice Qualité / Quality DirectorReveal Email/Phone
6
Associate Director Advanced Cell ManufacturingReveal Email/Phone
7
Project ManagerReveal Email/Phone
8
Project ManagerReveal Email/Phone
9
QC Operations ManagerReveal Email/Phone
10
Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$25.9M1813%$150.5MN/A
#2
$28.4M183-56%N/AN/A
#3
$4.3M288%N/AN/A
#4
$55.6M3591%N/AN/A
#5
$11M7120%N/AN/A
#6
$22.2M143-22%N/AN/A
#7
$4.2M2713%N/AN/A
#8
$2M130%N/AN/A
#9
$295.7M19085%N/AN/A
#10
$2.8M186%N/AN/A
Add Company

What Is C3i?

C3i, a Centre of Excellence for Commercialisation and Research, will accelerate access to innovative therapies in immuno-oncology and regenerative medicine for patients. Operating in Montreal, Canada, C3i offers an integrated structure for the development, translation and commercialisation of these ground breaking therapies. Acting as a \one-stop-shop\ solution for the development, translation, and commercialisation of cancer immunotherapy, C3i combines four interacting units: - GMP Manufacturing Unit for Regenerative Medicine and Cancer Immunotherapy - Biomarker-Diagnostic Unit - Clinical Research Unit and a CRO - Innovation and Commercialisation Unit

keywords:N/A

N/A

Total Funding

118

Number of Employees

$18.3M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M1187%N/A
#2
$28.2M118-8%N/A
#3
$14.2M1186%N/A
#4
$17.1M118-19%N/A
#5
$24.8M1189%N/A